Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 2.41 +0.01 (0.62%)
price chart
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) Short Interest Update
The short interest in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has increased from 729,625 on June 30,2015 to 953,755 on July 15,2015.
Company Shares of Pluristem Therapeutics, Inc. Drops by -6.53%
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has lost 6.53% during the past week and dropped 10.55% in the last 4 weeks.
Scientific Study Published in 'Stem Cells' Show Pluristem's PLX Cells Regulate ...
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced the publication of a scientific study regarding PLacental eXpanded (PLX) cells in the prominent peer-reviewed journal Stem Cells.
New Data Show Pluristem's PLX Cells Regulate the Immune System  MarketWatch
New Data Show Pluristem''s PLX Cells Regulate the Immune System  Nasdaq
Pluristem Therapeutics Inc.'s PLX Cells Get Green Light For Fast Track ...
Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, it appears the fantasy may become reality, featuring Pluristem Therapeutics Inc. (NASDAQ:PSTI) as its ...
Pluristem Therapeutics's Buy Rating Reiterated at Maxim Group (PSTI)  The Legacy
Short Interest Update of Pluristem Therapeutics, Inc. (NASDAQ:PSTI)
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) stated loss of 222,269 shares or 23.4% in the short interest. The short interest registered from 951,894 on June 15,2015 to 729,625 on June 30,2015.
Company Shares of Pluristem Therapeutics, Inc. Drops by -2.44%  The Daily Rover
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Maxim Weighs in on Biotech Stocks: Sophiris Bio Inc (SPHS), Pluristem ...
Maxim Group's healthcare analyst Jason Kolbert weighed in today with research reports on the Canadian urology company Sophiris Bio Inc (NASDAQ:SPHS), Israeli stem cell company Pluristem Therapeutics Inc. (NASDAQ:PSTI), and Ontario-based ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a Buy: MLV & Co
In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI). The analyst placed a $6.00 price target on the stock which indicates a 105.48% upside to the last closing price.
Pluristem Therapeutics, Inc. Short Interest Update
Pluristem Therapeutics, Inc. (NASDAQ:PSTI), A rise of 72,647 shares or 8.3% was seen in the short interest of Pluristem Therapeutics, Inc.. Even as the interest increased from 879,247 shares on May 29,2015 to 951,894 shares on June 15,2015, the days to ...
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Pluristem Announces Significant New Finding From Its Phase I/II Muscle ...  GlobeNewswire (press release)